Floatz logo

Gm-Csf

Liver Cell Carcinoma, Adult

Lisa H. Butterfield, Ph.D.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Liver Cell Carcinoma, Adult cohort.

Asset / SponsorPhaseRating
Sorafenib
Roswell Park Cancer Institute
Phase 3BBB
Inno-206
Case Comprehensive Cancer Center
Phase 3BB
Irinotecan
University of Chicago
Phase 2BB
Eloxatin
Case Comprehensive Cancer Center
Phase 2BB
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Gm-Csf is also rated in:

melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →